Highlights

  • Licensing deals allow ASX biotechs to share risk while accessing capital, expertise and global commercial networks.
  • Royalty-based models, like Neuren’s, offer capital-efficient growth but reduce full commercial upside.
  • Interest rates significantly impact biotech valuations due to their reliance on future cash flows.
  • AUD/USD movements directly affect earnings, with a weaker Australian dollar generally benefiting global-facing biotechs.
  • Partnership announcements often act as major catalysts, validating technology and driving share price re-ratings.
  • Strong governance and transparent clinical data disclosure are critical in managing biotech investment risk.

The Role of Partnerships and Licensing in ASX Biotech

Partnerships and licensing agreements are a critical component of the ASX biotech business model. Given the relatively small size of most Australian biotech companies and the enormous costs associated with late-stage clinical development and global commercialisation, partnerships with larger pharmaceutical companies provide a means of accessing the capital, infrastructure, and expertise needed to bring products to market.

The most common partnership structure involves a licensing agreement in which the biotech company grants a larger pharmaceutical partner the rights to develop and commercialise a product in specific territories or therapeutic areas in exchange for upfront payments, milestone payments linked to development and commercial achievements, and ongoing royalties on product sales. This structure allows the biotech company to share the risk and cost of development while retaining the potential for significant financial returns through royalties.

Neuren Pharmaceuticals provides a textbook example of the licensing model in action. The company developed trofinetide through early clinical stages and then licensed the compound to Acadia Pharmaceuticals for late-stage development and commercialisation. Neuren retained royalty rights on sales, which now generate over sixty-four million Australian dollars annually. This revenue stream requires minimal ongoing investment from Neuren, creating a highly capital-efficient business model that funds the company's proprietary pipeline development.

However, partnerships also carry risks. Companies that license their most valuable assets may give up the majority of the commercial upside, particularly if the product becomes a blockbuster. The partner's strategic priorities may not always align with the biotech company's interests, and changes in the partner's leadership, pipeline priorities, or financial circumstances can affect the pace and intensity of development efforts. Neuren's dependence on Acadia for DAYBUE commercialisation illustrates this risk: any challenges at Acadia could directly impact Neuren's royalty income.

For investors evaluating ASX biotech companies, the terms of existing and potential partnerships are important valuation factors. Key questions to consider include the milestone and royalty rates, the territories and indications covered, the partner's financial strength and strategic commitment to the programme, and whether the biotech company retains any co-promotion or co-development rights. Companies with favourable partnership terms and financially strong partners are generally better positioned than those that have either given away too much economics or are dependent on partners with uncertain commitment.

The potential for new partnerships is also a significant source of value for ASX biotech companies. Positive clinical trial results can attract partnership interest from larger companies, with the terms of a deal often reflecting the de-risked nature of the asset. Companies approaching Phase 3 trials or with positive Phase 2 data are typically in the strongest position to negotiate favourable partnerships, as the data provides evidence of efficacy that reduces the partner's risk.

Immutep's collaboration with Merck to evaluate its lead asset in combination with Keytruda, and AcroImmune's merger with OncoC4 to advance a PD-1/VEGF bispecific antibody, are recent examples of the types of partnerships and transactions that can create value for ASX biotech shareholders. Investors should monitor partnership announcements closely, as they often represent significant validation of a company's technology and can serve as positive catalysts for share price appreciation.

Currency, Macroeconomic Factors, and Their Impact

 

The performance of ASX biotech stocks is influenced not only by company-specific factors but also by broader macroeconomic conditions, including interest rates, currency movements, and global risk sentiment. Understanding these macroeconomic dynamics can help investors time their allocations and manage portfolio risk more effectively.

Interest rates have a particularly pronounced impact on biotech valuations. Because many biotech companies do not generate current earnings and their value is derived from future cash flows, they are especially sensitive to changes in discount rates. When interest rates rise, the present value of those future cash flows decreases, putting downward pressure on biotech valuations. Conversely, when rates fall, biotech stocks tend to benefit from the lower discount rate applied to their expected future earnings. The interest rate environment of 2023 to 2025, characterised by elevated rates following a period of aggressive central bank tightening, weighed on biotech valuations globally and contributed to the underperformance of many ASX biotech stocks relative to their fundamental progress.

Currency movements are another important factor, particularly the AUD/USD exchange rate. Australian biotech companies with US dollar revenue, US operations, or US clinical development programmes are directly affected by currency fluctuations. A weakening Australian dollar is generally positive for these companies, as it increases the Australian dollar value of their US dollar revenue and assets. Conversely, a strengthening Australian dollar reduces the translated value of US operations and can weigh on reported earnings.

The Australian dollar is traditionally classified as a risk currency, meaning it tends to appreciate during periods of positive global risk sentiment and depreciate during risk-off environments. This characteristic creates a natural hedge for Australian investors holding US dollar-denominated biotech assets: when markets sell off and the Australian dollar weakens, the currency movement partially offsets the decline in the underlying asset value. However, this hedge is imperfect and can work against investors during risk-on environments when the Australian dollar strengthens.

For retail investors managing currency risk, several approaches are available. The simplest is to accept currency fluctuations as part of the investment and focus on the underlying business fundamentals. For investors who wish to hedge currency exposure, currency-hedged ETFs and forward currency contracts provide tools to reduce currency-related volatility, though they come with their own costs and complexities. The decision to hedge should be based on the investor's time horizon, the proportion of their portfolio exposed to foreign currency, and their tolerance for currency-related volatility.

Global risk sentiment, often driven by geopolitical events, economic data releases, and central bank communications, can also impact biotech stocks disproportionately. During periods of heightened uncertainty, investors tend to shift capital from growth-oriented sectors like biotech to defensive sectors like utilities and consumer staples. This rotation can create selling pressure on biotech stocks that is unrelated to company fundamentals. For long-term investors, such periods of indiscriminate selling can create attractive entry points in high-quality biotech names.

Trade policy and tariffs have emerged as an increasingly relevant consideration for biotech investors. Companies with global supply chains, particularly those manufacturing in one country and selling in another, can be affected by changes in tariff regimes. Clarity Pharmaceuticals' decision to establish US-based manufacturing partly reflects a desire to mitigate tariff risk, and other ASX biotechs with significant US commercial operations may face similar considerations. Investors should monitor trade policy developments and assess the exposure of their portfolio companies to tariff-related risks.

Environmental, Social, and Governance Considerations in Biotech Investing

 

Environmental, social, and governance considerations have become increasingly important for investors across all sectors, and biotech is no exception. While biotech companies may not face the same environmental scrutiny as mining or energy companies, they operate in a space with profound social implications, and governance standards can significantly impact shareholder outcomes.

From a social perspective, biotech companies are fundamentally in the business of improving human health. The treatments developed by ASX biotech companies address some of the most serious and debilitating conditions known to medicine, from cancer and heart failure to rare genetic disorders and drug-resistant infections. For investors who prioritise social impact alongside financial returns, biotech investing offers the opportunity to support companies that are directly contributing to better health outcomes for patients worldwide.

However, the social dimension of biotech investing also encompasses more challenging questions, including drug pricing and access, the ethics of clinical trial design and patient recruitment, and the equitable distribution of therapeutic benefits across different populations and geographies. Companies that pursue responsible pricing strategies, conduct ethical clinical trials, and work to expand access to their products beyond wealthy markets may be better positioned for long-term success, as they are less likely to face regulatory backlash, reputational damage, or political pressure to reduce prices.

Governance is particularly important in biotech investing because of the highly technical nature of the business and the significant information asymmetry between management and shareholders. Strong governance practices, including independent board oversight, transparent communication of clinical trial results, responsible capital allocation, and alignment of executive compensation with shareholder value creation, are hallmarks of well-managed biotech companies. Investors should pay attention to the composition of the board of directors, the independence and expertise of board members, and the track record of management in delivering on stated milestones and financial targets.

One area where governance concerns are particularly acute in biotech is in the disclosure of clinical trial results. Companies that selectively disclose positive results while obscuring negative data, or that present results in misleading ways, undermine investor trust and can create significant valuation distortions. Investors should favour companies that adhere to best practices in clinical trial disclosure, including pre-registration of trial endpoints, timely publication of results regardless of outcome, and transparent communication of safety data.

Capital allocation is another governance issue that affects biotech investors. Management teams that deploy capital efficiently, focusing on the highest-value clinical programmes and avoiding the temptation to pursue too many programmes simultaneously, are more likely to create shareholder value. Conversely, companies that spread their resources too thin across multiple programmes, or that pursue vanity projects without clear commercial potential, are at greater risk of value destruction. Clinuvel's disciplined approach to capital allocation, maintaining profitability and avoiding dilution for over a decade, exemplifies the kind of governance that biotech investors should seek.